# Centers for Disease Control and Prevention

Type: organization

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/centers-for-disease-control-and-prevention
Canonical HTML page: https://getbiobrief.com/entity/centers-for-disease-control-and-prevention

## Recent coverage (3 stories)

### Cyclospora Outbreak in 18 States Exposes Unmet Need for Rapid Parasitic Diagnostics
2026-07-11 18:38:22 · Sentiment: Negative · Impact: 6/10 · Sources: 24

With symptoms lasting weeks and no routine test, the cyclosporiasis outbreak across 18 states reveals a significant market opportunity for biotech companies developing rapid, point-of-care diagnostic assays. Over 1,250 cases in Michigan alone highlight the need for innovation.
Full story: https://getbiobrief.com/story/cyclospora-diagnostic-opportunity-biotech

### South Carolina Spends $1.6M on Ongoing Measles Outbreak as Costs Mount
2026-03-13 21:34:29 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

South Carolina health officials have already allocated $1.6 million to contain a significant measles outbreak that shows no signs of immediate resolution. The expenditure highlights the massive economic burden of vaccine-preventable diseases on state public health infrastructures.
Full story: https://getbiobrief.com/story/south-carolina-measles-outbreak-costs-2026

### New York Issues Urgent Health Alert as Drug-Resistant Fungal Pathogen Spreads
2026-02-27 03:06:27 · Sentiment: Strongly negative · Impact: 8/10 · Sources: 2

New York health authorities have issued a high-level alert regarding the accelerated spread of a deadly, drug-resistant fungal pathogen across healthcare facilities. The pathogen, identified as Candida auris, poses a severe threat to immunocompromised patients and highlights a critical gap in the current antifungal pharmaceutical pipeline.
Full story: https://getbiobrief.com/story/new-york-fungal-alert-candida-auris-spread

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.